Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG
激素敏感性乳腺癌女性芳香化酶抑制剂相关骨丢失（AIBL）的管理：国际骨质疏松症基金会（IOF）、美国乳腺癌学会（CABS）、欧洲肿瘤学会（ECTS）、国际骨质疏松症专家组（IEG）、欧洲乳腺癌和骨质疏松症协会（ESCEO）、国际骨质疏松症协会（IMS）和国际骨质疏松症协会（SIOG）联合立场声明更新
期刊:Journal of Bone Oncology
影响因子:3.5
doi:10.1016/j.jbo.2025.100694
Hadji, Peyman; Aapro, Matty; Al-Dagri, Nasser; Alokail, Majed; Biver, Emmanuel; Body, Jean-Jacques; Brandi, Maria Luisa; Brown, Janet; Confavreux, Cyrille; Cortet, Bernard; Drake, Matthew; Ebeling, Peter; Eriksen, Erik Fink; Fuleihan, Ghada El-Hajj; Guise, Theresa A; Harvey, Nick C; Kurth, Andreas; Langdahl, Bente; Lems, Willem; Matijevic, Radmila; McCloskey, Eugene; Nappi, Rossella; Palacios, Santiago; Pfeiler, Georg; Reginster, Jean-Yves; Rizzoli, René; Santini, Daniele; Tuzun, Sansin; Poznak, Catherine Van; Villiers, Tobias De; Zillikens, M Carola; Coleman, Robert
肿瘤
肿瘤免疫
多发性硬化症
乳腺癌
代谢
骨质疏松
免疫/内分泌
